Alzeca Biosciences said today that it raised $11 million in a Series A round to fund the development of its MRI imaging agent designed for the early diagnosis of Alzheimer’s disease and other neurodegenerative disorders.
The company touts its ADx nanoparticle as the first MRI contrast agent to target amyloid – a brain protein linked to Alzheimer’s disease. Alzeca said that its newly-acquired funds will help bring its imaging compound through Phase I clinical trials.
Get the full story at our sister site, Drug Delivery Business News.
The post Alzeca Biosciences raises $11m for Alzheimer’s diagnostic imaging agent appeared first on MassDevice.
from MassDevice http://ift.tt/2uTZ1FU
Cap comentari:
Publica un comentari a l'entrada